Oral curcumin for Alzheimer's disease: Tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study

Alzheimer's Research and Therapy

Volumn 4, Issue 5, 2012, Pages

  Ringman, John M ^a   Frautschy, Sally A ^a,b   Teng, Edmond ^a,b   Begum, Aynun N ^a   Bardens, Jenny ^a   Beigi, Maryam ^a   Gylys, Karen H ^a,c   Badmaev, Vladimir ^d   Heath, Dennis D ^e   Apostolova, Liana G ^a   Porter, Verna ^a   Vanek, Zeba ^a   Marshall, Gad A ^f   Hellemann, Gerhard ^g   Sugar, Catherine ^g   Masterman, Donna L ^h   Montine, Thomas J ⁱ   Cummings, Jeffrey L ^j   Cole, Greg M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d AMH Corporation   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h F HOFFMANN LA ROCHE LTD   (Switzerland)

ⁱ UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^j CLEVELAND CLINIC LOU RUVO CENTER FOR BRAIN HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CURCUMIN; CURCUMIN C3 COMPLEX; DRUG METABOLITE; ISOPROSTANE DERIVATIVE; P TAU181 PROTEIN; PLACEBO; T TAU PROTEIN; TAU PROTEIN; TETRAHYDROCURCUMIN; UNCLASSIFIED DRUG;

ABNORMAL FECES; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOCRIT; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 84867901639     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/alzrt146     Document Type: Article

References (26)

1. 2011 Alzheimer's disease facts and figures. Thies W, Bleiler L, Alzheimers Dement 2011 7 208 244 21414557
2. Studies on spice principles as antioxidants in the inhibition of lipid peroxidation of rat liver microsomes. Reddy AC, Lokesh BR, Mol Cell Biochem 1992 111 117 124 1588934
3. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR, Neurology 2005 64 1152 1156 10.1212/01.WNL.0000156156.13641.BA 15824339
4. Inflammation in Alzheimer's disease. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al. Neurobiol Aging 2000 21 383 421 10.1016/S0197-4580(00)00124-X 10858586 (Pubitemid 30349107)
5. A potential role of the curry spice curcumin in Alzheimer's disease. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL, Curr Alzheimer Res 2005 2 131 136 10.2174/1567205053585882 15974909 (Pubitemid 40862872)
6. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA, J Pharmacol Exp Ther 2008 326 196 208 10.1124/jpet.108.137455 18417733 (Pubitemid 351872144)
7. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult. Kim DS, Park SY, Kim JK, Neurosci Lett 2001 303 57 61 10.1016/S0304-3940(01)01677-9 11297823 (Pubitemid 32285467)
8. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. Ono K, Hasegawa K, Naiki H, Yamada M, J Neurosci Res 2004 75 742 750 10.1002/jnr.20025 14994335 (Pubitemid 38296087)
9. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM, J Neurosci 2001 21 8370 8377 11606625 (Pubitemid 33051435)
10. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ, J Neurochem 2007 102 1095 1104 10.1111/j.1471-4159.2007.04613.x 17472706 (Pubitemid 47174225)
11. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Sharma RA, McLelland HR, Hill KA, Ireson CR, Euden SA, Manson MM, Pirmohamed M, Marnett LJ, Gescher AJ, Steward WP, Clin Cancer Res 2001 7 1894 1900 11448902 (Pubitemid 32994823)
12. NTP Toxicology and Carcinogenesis Studies of Turmeric Oleoresin (CAS No. 8024-37-1). (Major Component 79%-85% Curcumin CAS No, 458-37-7) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 1993 427 1 275 12616304
13. Diagnostic and Statistical Manual of Mental Disorders Washington: American Psychiatric Association 4 1994
14. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM, Neurology 1984 34 939 944 10.1212/WNL.34.7.939 6610841 (Pubitemid 14076461)
15. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ, Alzheimer Dis Assoc Disord 1997 11 Suppl 2 13 21 9236948
16. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J, Neurology 1994 44 2308 2314 10.1212/WNL.44.12.2308 7991117 (Pubitemid 24382728)
17. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S, Alzheimer Dis Assoc Disord 1997 11 Suppl 2 33 39 9236950
18. Suppression of murine cerebral F2-isoprostanes and F4-neuroprostanes from excitotoxicity and innate immune response in vivo by alpha- or gamma-tocopherol. Milatovic D, VanRollins M, Li K, Montine KS, Montine TJ, J Chromatogr B Analyt Technol Biomed Life Sci 2005 827 88 93 10.1016/j.jchromb. 2005.03.037 16260380 (Pubitemid 41551601)
19. Curcumin in plasma and urine: quantitation by high-performance liquid chromatography. Heath DD, Pruitt MA, Brenner DE, Rock CL, J Chromatogr B Analyt Technol Biomed Life Sci 2003 783 287 295 10.1016/S1570-0232(02)00714-6 12450549 (Pubitemid 35351656)
20. Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration. Garcea G, Jones DJ, Singh R, Dennison AR, Farmer PB, Sharma RA, Steward WP, Gescher AJ, Berry DP, Br J Cancer 2004 90 1011 1015 10.1038/sj.bjc.6601623 14997198 (Pubitemid 38499692)
21. Biotransformation of curcumin through reduction and glucuronidation in mice. Pan MH, Huang TM, Lin JK, Drug Metab Dispos 1999 27 486 494 10101144
22. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, Cole GM, Neurobiol Aging 2001 22 993 1005 10.1016/S0197-4580(01)00300-1 11755008 (Pubitemid 34070638)
23. Antioxidants for Alzheimer Disease:a randomized clinical trial with cerebrospinal fluid biomarker measures. Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P, Arch Neurol
24. A pilot cross-over study to evaluate human oral bioavailability of BCM-95CG (Biocurcumax), a novel bioenhanced preparation of curcumin. Antony B, Merina B, Iyer VS, Judy N, Lennertz K, Joyal S, Indian J Pharm Sci 2008 70 445 449 10.4103/0250-474X.44591 20046768
25. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V, J Clin Psychopharmacol 2008 28 110 113 10.1097/jcp.0b013e318160862c 18204357
26. Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Kokjohn TA, Roher AE, Alzheimers Dement 2009 5 340 347 10.1016/j.jalz.2009.03.002 19560104